[1]Okuno T, Isobe T, Tsubata Y. Current pharmacologic treatment of brain metastasis in non-small cell lung cancer. Clin Exp Metastasis. 2024 Oct;41(5):549-565. doi: 10.1007/s10585-024-10276-4. Epub 2024 Mar 11. PMID: 38466521; PMCID: PMC11499348.
[2]Jung HA, Park S, Lee SH, et al. Dacomitinib in EGFR-mutant non-small-cell lung cancer with brain metastasis: a single-arm, phase II study. 2023, ESMO Open 8:102068.
[3]Jin H, Liang P, Hou J, et al. The efficacy and safety of Afatinib in non-small cell lung cancer patients with brain metastasis: a meta-analysis. J Oncol 2023:5493725.
[4]Reungwetwattana T, Nakagawa K, Cho BC, et al. CNS response to osimertinib versus standard epidermal growth factor receptor tyrosine kinase inhibitors in patients with untreated EGFR-mutated advanced non-small-cell lung cancer. J Clin Oncol. 2018;36:3290-3297.
[5]P. Janne, D. Planchard, Y. Cheng, et al. Osimertinib With/Without Platinum-Based Chemotherapy as First-line Treatment in Patients with EGFRm Advanced NSCLC (FLAURA2). 2023 WCLC. Abstract PL03.13.
[6]Shi Y, Chen G, Wang X, et al. Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, double-blind, randomised phase 3 study. Lancet Respir Med. 2022;10(11):1019-1028.
[7]Shun Lu , Xiaorong Dong , Hong Jian, et al. Central nervous system efficacy of aumolertinib versus gefitinib in patients with untreated, EGFR-mutated, advanced non-small cell lung cancer: data from a randomized phase III trial (AENEAS). Cancer Commun (Lond). 2024 Sep;44(9):1005-1017.
[8]Passaro A, Wang J, Wang Y, et al. Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study. Ann Oncol ,2023, S0923–7534:04281–04283.
[9]Enriqueta Felip, et al. Amivantamab plus lazertinib vs osimertinib in first-line EGFR-mutant advanced non-small cell lung cancer (NSCLC) with biomarkers of high-risk disease: A secondary analysis from the phase 3 MARIPOSA study. 2024 ASCO. Abstract 8504.
[10]Costa DB, Shaw AT, Ou SH, et al. Clinical experience with crizotinib in patients with advanced ALK-rearranged non-small-cell lung cancer and brain metastases. J Clin Oncol, 2014, 33:1881–1888.
[11]Gadgeel SM, Gandhi L, Riely GJ, et al. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study. Lancet Oncol ,2014,15:1119–1128.
[12]Gadgeel SM, Gandhi L, Riely GJ, et al (2014) Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study. Lancet Oncol 15:1119–1128.
[13]Solomon B J, Liu G, Felip E, et al. Lorlatinib Versus Crizotinib in Patients With Advanced ALK-Positive Non–Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study[J]. Journal of Clinical Oncology, 2024: JCO. 24.00581.
[14]Bergethon K, Shaw AT, Ou SH, et al (2012) ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol 30:863–870.
[15]Wu YL, Yang JC, Kim DW, et al (2018) Phase II study of crizotinib in East Asian patients with ROS1-positive advanced non-small-cell lung cancer. J Clin Oncol 36:1405–1411.
[16]Costa DB, Shaw AT, Ou SH, et al (2014) Clinical experience with crizotinib in patients with advanced ALK-rearranged non-small-cell lung cancer and brain metastases. J Clin Oncol 33:1881–1888.
[17]Kim YH, Ozasa H, Nagai H,et al (2013) High-dose crizotinib for brain metastases refractory to standard-dose crizotinib. J Thorac Oncol 8:e85–e86.
[18]Dziadziuszko R, Krebs MG, Braud FD, et al (2021) Updated integrated analysis of the efficacy and safety of entrectinib in locally advanced or metastatic ROS1 fusion–positive non–small-cell lung cancer. J Clin Oncol 39:1253–1263.
[19]De Carlo E, Bertoli E, Del Conte A, et al (2022) Brain metastases management in oncogene-addicted non-small cell lung cancer in the targeted therapies era. Int J Mol Sci 23:6477.
[20]Trastuzumab deruxtecan (T-DXd) in patients with HER2-mutant metastatic non–small cell lung cancer (mNSCLC): Final analysis results of DESTINY-Lung02. Abstract 8543. 2024 ASCO.
[21]Yu HA, Goto Y, Hayashi H, et al (2023) HERTHENA-Lung01, a phase II trial of patritumab deruxtecan (HER3-DXd) in epidermal growth factor receptor-mutated non-small-cell lung cancer after epidermal growth factor receptor tyrosine kinase inhibitor therapy and platinum-based chemotherapy. J Clin Oncol 41:5363–5375.
[22]Chu X, Niu L, Xiao G, et al (2022) the long-term and short-term efficacy of immunotherapy in non-small cell lung cancer patients with brain metastases: a systematic review and meta-analysis. Front Immunol 13:875488.
[23]Shaverdian N, Lisberg AE, Bornazyan K, et al (2017) Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial. Lancet Oncol 18:895–903.